The effects of bisphosphonates on disease activity and bone status in ankylosing spondylitis (BIAS)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN87639321

Enrollment

180

Registered

2005-05-23

Start date

2004-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing Spondylitis (AS) Musculoskeletal Diseases Ankylosing Spondylitis (AS)

Interventions

Placebo or Alendronate 70 mg weekly

Eligibility

Inclusion criteria

Inclusion criteria: Age > 21, stable dose of non-steroidal anti-inflammatory drug (NSAID) for last four weeks. Need to fulfil New York Criteria for AS.

Exclusion criteria

Exclusion criteria: 1. Systemic steroids for the last three months 2. Bisphosphonates in the last 12 months 3. Oesophageal disease or active peptic ulcer 4. Unable to give informed consent 5. Known Paget's Disease 6. Renal disease with creatinine >150 mmol/l, hypercalcaemia, osteomalacia, inflammatory bowel disease, known malignancy and reduced life expectancy <2 years

Design outcomes

Primary

Measure	Time frame
BAS-G	—

Secondary

Measure	Time frame
BASDAI, BASFI and BASRI, ESR, CRP, use of NSAIDs, bone density and vertebral deformity.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026